Gilead Sciences (GILD) Stock Analysis
Gilead Sciences trades on the NASDAQ under the ticker GILD. StonkBuddy files it under Healthcare. It is in the S&P 500.
GILD price context
- 52-week range: $114.02 to $160.51 (as of October 23, 2026)
- Market value: about $189.80 billion (October 19, 2026)
Next earnings
Gilead Sciences is expected to report results on October 29, 2026, after the market closes. Earnings calendar
Congress trades in GILD
In the last 12 months, members of Congress reported 4 trades in GILD (House and Senate disclosure reports). The latest reported:
- Jared Moskowitz: Bought, $1,001 - $15,000, traded May 6, 2026, reported June 19, 2026 (filing)
- Jared Moskowitz: Bought, $1,001 - $15,000, traded May 6, 2026, reported June 19, 2026 (filing)
- Alan Armstrong: Bought, $1,001 - $15,000, traded March 27, 2026, reported July 21, 2026 (filing)
- Josh Gottheimer: Bought, $1,001 - $15,000, traded January 27, 2026, reported February 26, 2026 (filing)
- Val T. Hoyle: Sold, $1,001 - $15,000, traded September 23, 2025, reported October 10, 2025 (filing)
All Congress trades · Filed this week
Insider trades in GILD
Since September 30, 2026, Gilead Sciences's officers, directors and large owners have filed 3 open-market buys and sales of its shares (SEC Form 4). The latest reported:
- Johanna Mercier, Chief Comm & Corp Aff Officer, sold 3,000 shares at $156.22 on October 15, 2026, reported October 16, 2026 (Form 4)
- Andrew D Dickinson, Chief Financial Officer, sold 3,000 shares at $156.22 on October 15, 2026, reported October 16, 2026 (Form 4)
- Daniel Patrick O'Day, Chairman & CEO, sold 3,000 shares at $148.63 on October 1, 2026, reported October 2, 2026 (Form 4)
- Daniel Patrick O'Day, Chairman & CEO, sold 12,000 shares at $147.72 on October 1, 2026, reported October 2, 2026 (Form 4)
Members also see the StonkBuddy score for GILD on this page. What the score means